nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—UGT1A9—Estrogen metabolism—COMT—conduct disorder	0.041	0.041	CbGpPWpGaD
Buprenorphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0286	0.0286	CbGpPWpGaD
Buprenorphine—OPRL1—Circadian rythm related genes—SLC6A4—conduct disorder	0.0242	0.0242	CbGpPWpGaD
Buprenorphine—CYP1A2—Methylation—COMT—conduct disorder	0.024	0.024	CbGpPWpGaD
Buprenorphine—OPRL1—Circadian rythm related genes—DRD4—conduct disorder	0.0228	0.0228	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR ligand binding—CGA—conduct disorder	0.0218	0.0218	CbGpPWpGaD
Buprenorphine—OPRL1—G alpha (i) signalling events—DRD4—conduct disorder	0.0201	0.0201	CbGpPWpGaD
Buprenorphine—OPRL1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0187	0.0187	CbGpPWpGaD
Buprenorphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.016	0.016	CbGpPWpGaD
Buprenorphine—CYP2C18—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0159	0.0159	CbGpPWpGaD
Buprenorphine—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.015	0.015	CbGpPWpGaD
Buprenorphine—CYP2C19—Melatonin metabolism and effects—MAOA—conduct disorder	0.0131	0.0131	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—CGA—conduct disorder	0.0123	0.0123	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0122	0.0122	CbGpPWpGaD
Buprenorphine—OPRL1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0122	0.0122	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR ligand binding—DRD4—conduct disorder	0.0122	0.0122	CbGpPWpGaD
Buprenorphine—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.012	0.012	CbGpPWpGaD
Buprenorphine—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.0116	0.0116	CbGpPWpGaD
Buprenorphine—UGT1A9—Phase II conjugation—COMT—conduct disorder	0.0115	0.0115	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—CGA—conduct disorder	0.0112	0.0112	CbGpPWpGaD
Buprenorphine—CYP2C18—FOXA1 transcription factor network—EP300—conduct disorder	0.0109	0.0109	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0107	0.0107	CbGpPWpGaD
Buprenorphine—CYP3A7—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0106	0.0106	CbGpPWpGaD
Buprenorphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0104	0.0104	CbGpPWpGaD
Buprenorphine—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.0102	0.0102	CbGpPWpGaD
Buprenorphine—UGT1A9—NRF2 pathway—SLC6A4—conduct disorder	0.0101	0.0101	CbGpPWpGaD
Buprenorphine—CYP2A6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0097	0.0097	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—CGA—conduct disorder	0.00929	0.00929	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00904	0.00904	CbGpPWpGaD
Buprenorphine—ABCG2—HIF-2-alpha transcription factor network—EP300—conduct disorder	0.00896	0.00896	CbGpPWpGaD
Buprenorphine—OPRD1—G alpha (i) signalling events—DRD4—conduct disorder	0.00859	0.00859	CbGpPWpGaD
Buprenorphine—CYP2C18—Biological oxidations—COMT—conduct disorder	0.00852	0.00852	CbGpPWpGaD
Buprenorphine—CYP2C18—Biological oxidations—MAOA—conduct disorder	0.00846	0.00846	CbGpPWpGaD
Buprenorphine—CYP2C18—Metapathway biotransformation—COMT—conduct disorder	0.0084	0.0084	CbGpPWpGaD
Buprenorphine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00829	0.00829	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CGA—conduct disorder	0.00814	0.00814	CbGpPWpGaD
Buprenorphine—OPRD1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00797	0.00797	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR ligand binding—HTR2A—conduct disorder	0.00795	0.00795	CbGpPWpGaD
Buprenorphine—OPRL1—Circadian rythm related genes—EP300—conduct disorder	0.00788	0.00788	CbGpPWpGaD
Buprenorphine—CYP2A6—NRF2 pathway—SLC6A4—conduct disorder	0.00781	0.00781	CbGpPWpGaD
Buprenorphine—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00765	0.00765	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—DRD4—conduct disorder	0.00753	0.00753	CbGpPWpGaD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00699	0.00699	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—DRD4—conduct disorder	0.00688	0.00688	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CGA—conduct disorder	0.00688	0.00688	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00683	0.00683	CbGpPWpGaD
Buprenorphine—UGT1A9—Biological oxidations—COMT—conduct disorder	0.00673	0.00673	CbGpPWpGaD
Buprenorphine—UGT1A9—Biological oxidations—MAOA—conduct disorder	0.00669	0.00669	CbGpPWpGaD
Buprenorphine—UGT1A9—Metapathway biotransformation—COMT—conduct disorder	0.00664	0.00664	CbGpPWpGaD
Buprenorphine—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00663	0.00663	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CGA—conduct disorder	0.00659	0.00659	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—DRD4—conduct disorder	0.00636	0.00636	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—DRD4—conduct disorder	0.00625	0.00625	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00599	0.00599	CbGpPWpGaD
Buprenorphine—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00592	0.00592	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00591	0.00591	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00573	0.00573	CbGpPWpGaD
Buprenorphine—CYP3A7—Biological oxidations—COMT—conduct disorder	0.00566	0.00566	CbGpPWpGaD
Buprenorphine—CYP3A7—Biological oxidations—MAOA—conduct disorder	0.00562	0.00562	CbGpPWpGaD
Buprenorphine—CYP3A7—Metapathway biotransformation—COMT—conduct disorder	0.00559	0.00559	CbGpPWpGaD
Buprenorphine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00544	0.00544	CbGpPWpGaD
Buprenorphine—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00539	0.00539	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—WASF1—conduct disorder	0.00528	0.00528	CbGpPWpGaD
Buprenorphine—ABCG2—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00527	0.00527	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CGA—conduct disorder	0.00525	0.00525	CbGpPWpGaD
Buprenorphine—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0052	0.0052	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—DRD4—conduct disorder	0.0052	0.0052	CbGpPWpGaD
Buprenorphine—CYP2A6—Biological oxidations—COMT—conduct disorder	0.00519	0.00519	CbGpPWpGaD
Buprenorphine—CYP2A6—Biological oxidations—MAOA—conduct disorder	0.00515	0.00515	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00506	0.00506	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CGA—conduct disorder	0.00476	0.00476	CbGpPWpGaD
Buprenorphine—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00461	0.00461	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CGA—conduct disorder	0.0046	0.0046	CbGpPWpGaD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00456	0.00456	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—DRD4—conduct disorder	0.00456	0.00456	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—HTR2A—conduct disorder	0.00449	0.00449	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00446	0.00446	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00433	0.00433	CbGpPWpGaD
Buprenorphine—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.00422	0.00422	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CGA—conduct disorder	0.00418	0.00418	CbGpPWpGaD
Buprenorphine—UGT1A9—PPARA activates gene expression—EP300—conduct disorder	0.00413	0.00413	CbGpPWpGaD
Buprenorphine—CYP3A5—Biological oxidations—COMT—conduct disorder	0.00409	0.00409	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—HTR2A—conduct disorder	0.00408	0.00408	CbGpPWpGaD
Buprenorphine—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.00406	0.00406	CbGpPWpGaD
Buprenorphine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—conduct disorder	0.00404	0.00404	CbGpPWpGaD
Buprenorphine—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.00404	0.00404	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00391	0.00391	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CGA—conduct disorder	0.00389	0.00389	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00385	0.00385	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—DRD4—conduct disorder	0.00385	0.00385	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—DRD4—conduct disorder	0.00369	0.00369	CbGpPWpGaD
Buprenorphine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00356	0.00356	CbGpPWpGaD
Buprenorphine—CYP2C8—Biological oxidations—COMT—conduct disorder	0.00355	0.00355	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CGA—conduct disorder	0.00353	0.00353	CbGpPWpGaD
Buprenorphine—CYP2C8—Biological oxidations—MAOA—conduct disorder	0.00352	0.00352	CbGpPWpGaD
Buprenorphine—CYP2C8—Metapathway biotransformation—COMT—conduct disorder	0.0035	0.0035	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—HTR2A—conduct disorder	0.00339	0.00339	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0033	0.0033	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—CGA—conduct disorder	0.00323	0.00323	CbGpPWpGaD
Buprenorphine—CYP2C19—Biological oxidations—COMT—conduct disorder	0.00317	0.00317	CbGpPWpGaD
Buprenorphine—CYP2C19—Biological oxidations—MAOA—conduct disorder	0.00314	0.00314	CbGpPWpGaD
Buprenorphine—CYP2C19—Metapathway biotransformation—COMT—conduct disorder	0.00312	0.00312	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00304	0.00304	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00304	0.00304	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00302	0.00302	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—HTR2A—conduct disorder	0.00297	0.00297	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—DRD4—conduct disorder	0.00294	0.00294	CbGpPWpGaD
Buprenorphine—CYP2D6—Biological oxidations—COMT—conduct disorder	0.00291	0.00291	CbGpPWpGaD
Buprenorphine—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.00289	0.00289	CbGpPWpGaD
Buprenorphine—CYP2C9—Biological oxidations—COMT—conduct disorder	0.00289	0.00289	CbGpPWpGaD
Buprenorphine—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.00287	0.00287	CbGpPWpGaD
Buprenorphine—CYP2C9—Biological oxidations—MAOA—conduct disorder	0.00287	0.00287	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00285	0.00285	CbGpPWpGaD
Buprenorphine—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	0.00285	0.00285	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CGA—conduct disorder	0.00281	0.00281	CbGpPWpGaD
Buprenorphine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—conduct disorder	0.00278	0.00278	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00269	0.00269	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—DRD4—conduct disorder	0.00267	0.00267	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—DRD4—conduct disorder	0.00258	0.00258	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CGA—conduct disorder	0.00255	0.00255	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00251	0.00251	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CGA—conduct disorder	0.00247	0.00247	CbGpPWpGaD
Buprenorphine—CYP1A2—Biological oxidations—COMT—conduct disorder	0.00247	0.00247	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00245	0.00245	CbGpPWpGaD
Buprenorphine—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.00245	0.00245	CbGpPWpGaD
Buprenorphine—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.00243	0.00243	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—HTR2A—conduct disorder	0.00241	0.00241	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00234	0.00234	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—DRD4—conduct disorder	0.00234	0.00234	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—WASF1—conduct disorder	0.00226	0.00226	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00218	0.00218	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CGA—conduct disorder	0.00216	0.00216	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CGA—conduct disorder	0.00215	0.00215	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.0021	0.0021	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CGA—conduct disorder	0.00209	0.00209	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—WASF1—conduct disorder	0.00198	0.00198	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—DRD4—conduct disorder	0.00198	0.00198	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CGA—conduct disorder	0.00197	0.00197	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—HTR2A—conduct disorder	0.00192	0.00192	CbGpPWpGaD
Buprenorphine—CYP3A4—Biological oxidations—COMT—conduct disorder	0.0019	0.0019	CbGpPWpGaD
Buprenorphine—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.00189	0.00189	CbGpPWpGaD
Buprenorphine—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.00188	0.00188	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HTR2A—conduct disorder	0.00174	0.00174	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—HTR2A—conduct disorder	0.00168	0.00168	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—WASF1—conduct disorder	0.00167	0.00167	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—DRD4—conduct disorder	0.00158	0.00158	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CGA—conduct disorder	0.00155	0.00155	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HTR2A—conduct disorder	0.00153	0.00153	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—COMT—conduct disorder	0.00146	0.00146	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—MAOA—conduct disorder	0.00145	0.00145	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.00142	0.00142	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—DRD4—conduct disorder	0.00138	0.00138	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CGA—conduct disorder	0.00134	0.00134	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HTR2A—conduct disorder	0.00129	0.00129	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—EP300—conduct disorder	0.00128	0.00128	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00122	0.00122	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CGA—conduct disorder	0.0012	0.0012	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CGA—conduct disorder	0.00117	0.00117	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—DRD4—conduct disorder	0.00117	0.00117	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—COMT—conduct disorder	0.00115	0.00115	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—MAOA—conduct disorder	0.00114	0.00114	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00111	0.00111	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CGA—conduct disorder	0.0011	0.0011	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CGA—conduct disorder	0.00109	0.00109	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HTR2A—conduct disorder	0.00103	0.00103	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—COMT—conduct disorder	0.000977	0.000977	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—MAOA—conduct disorder	0.00097	0.00097	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—COMT—conduct disorder	0.000969	0.000969	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—MAOA—conduct disorder	0.000962	0.000962	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CGA—conduct disorder	0.000934	0.000934	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HTR2A—conduct disorder	0.000902	0.000902	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—COMT—conduct disorder	0.000888	0.000888	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—MAOA—conduct disorder	0.000881	0.000881	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HTR2A—conduct disorder	0.000762	0.000762	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CGA—conduct disorder	0.000721	0.000721	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—COMT—conduct disorder	0.0007	0.0007	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—MAOA—conduct disorder	0.000695	0.000695	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—EP300—conduct disorder	0.000625	0.000625	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—COMT—conduct disorder	0.000606	0.000606	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—MAOA—conduct disorder	0.000602	0.000602	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000584	0.000584	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EP300—conduct disorder	0.000545	0.000545	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—COMT—conduct disorder	0.000541	0.000541	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—MAOA—conduct disorder	0.000537	0.000537	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—COMT—conduct disorder	0.000528	0.000528	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—MAOA—conduct disorder	0.000525	0.000525	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000521	0.000521	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—COMT—conduct disorder	0.000498	0.000498	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—MAOA—conduct disorder	0.000494	0.000494	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—EP300—conduct disorder	0.000494	0.000494	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—COMT—conduct disorder	0.000494	0.000494	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—MAOA—conduct disorder	0.00049	0.00049	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EP300—conduct disorder	0.000478	0.000478	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000475	0.000475	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—COMT—conduct disorder	0.000422	0.000422	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—EP300—conduct disorder	0.000419	0.000419	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—MAOA—conduct disorder	0.000419	0.000419	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—EP300—conduct disorder	0.000415	0.000415	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000406	0.000406	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EP300—conduct disorder	0.000404	0.000404	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—EP300—conduct disorder	0.000381	0.000381	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—COMT—conduct disorder	0.000325	0.000325	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MAOA—conduct disorder	0.000323	0.000323	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—EP300—conduct disorder	0.0003	0.0003	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—EP300—conduct disorder	0.00026	0.00026	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—EP300—conduct disorder	0.000232	0.000232	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—EP300—conduct disorder	0.000227	0.000227	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—EP300—conduct disorder	0.000213	0.000213	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—EP300—conduct disorder	0.000212	0.000212	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—EP300—conduct disorder	0.000181	0.000181	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—EP300—conduct disorder	0.00014	0.00014	CbGpPWpGaD
